Ascendis Pharma A/S reported its fourth‑quarter and full‑year 2025 results, showing quarterly revenue of €248 million and total annual revenue of €720 million, a 98 % increase from the €364 million recorded in 2024.
The company posted a net loss of €228 million for 2025, compared with a €378 million loss in 2024. Cash and cash equivalents rose to €616 million from €560 million at the end of 2024, giving the company a solid liquidity cushion for ongoing pipeline development and commercial expansion.
Management attributed the revenue growth largely to the rapid expansion of its flagship product YORVIPATH. However, selling, general and administrative expenses climbed to €458 million from €291 million in 2024, reflecting intensified global commercial activities that contributed to the continued net loss.
Earnings per share for the quarter were €‑0.55, a miss against consensus estimates of roughly €‑0.15 to €‑0.06. The full‑year EPS was €‑3.76, underscoring the impact of higher operating costs on profitability despite strong top‑line momentum.
CEO Jan Mikkelsen said, "With a continued focus on making a meaningful difference for patients, we believe Ascendis is entering a steep growth phase as we transform into a leading global biopharma company." He added, "With strong execution and the power of our TransCon platform, we are positioned to generate approximately €500 million in operating cash flow in 2026 while aspiring to deliver at least €5 billion in global annual product revenue by 2030. At the same time, we are advancing a growing pipeline of highly differentiated programs to deliver durable, long‑term growth."
The company’s competitive landscape is intensifying, but progress on its TransCon CNP platform—now under FDA priority review with a PDUFA action date of February 28 2026—provides a potential new revenue stream. The announced $120 million share‑repurchase program for 2026 signals confidence in the company’s cash position and long‑term value creation.
Overall, Ascendis demonstrates strong commercial traction for YORVIPATH and a healthy cash balance, but the continued net loss and higher SG&A expenses highlight the investment phase the company is in. The EPS miss reflects the cost impact of expanding global operations, while the revenue growth and pipeline progress support a positive long‑term outlook.
The company’s strategic goal of €5 billion in global annual product revenue by 2030 and €500 million in operating cash flow in 2026 remains on track, underscoring management’s confidence in the company’s growth trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.